Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Fspecialisation%2Fneurology%2Fhigh-neda-rates-after-2-years-of-ocrelizumab%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=34.225.194.102&categories=Conference+Report+Article%7CNeurology%7CMultiple+Sclerosis%7CEAN+2020%7CMultiple+Sclerosis): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
High NEDA rates after 2 years of ocrelizumab - Medical Conferences

Home > Neurology > EAN 2020 > Multiple Sclerosis > High NEDA rates after 2 years of ocrelizumab

High NEDA rates after 2 years of ocrelizumab

Presented By
Prof. Patrick Vermersch, University of Lille, France

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
EAN 2020
Trial
Phase 3, CASTING
In the CASTING open-label single-arm prospective trial of ocrelizumab, the proportion of patients with no evidence of disease activity (NEDA) at year 2 was high: 74.8%–80.4% of patients were free of clinical disease activity, while 91.5% of patients were free of MRI activity [1]. NEDA was maintained from year 1 over year 2.

CASTING is a phase 3b study evaluating the efficacy and safety of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) patients with suboptimal response to 1 or 2 prior disease-modifying treatments (DMTs). The intention-to-treat (ITT) population included 680 patients. After 2 years, 74.8% of patients had NEDA; 80.4% had no evidence of clinical activity, 91.5% had no evidence of MRI activity, and 89.8% had no relapses.

The exploratory endpoint of 2-year NEDA with MRI from screening was reached by 52.0% of patients. This lower percentage was mainly due to the lower percentage of patients with no evidence of MRI activity, which dropped to 63.8%. The percentage of no evidence of clinical activity after 2 years was 80.6%. NEDA was maintained in year 2 when analysed by epoch. In the first epoch (baseline to year 1), NEDA was 82.6%, in the second epoch (year 1 to year 2) 87%.

Safety results over 2 years were consistent with prior studies, with no newly observed signals. In the ITT population of 680 patients, 49 (7.1%) experienced a serious adverse event, leading to treatment discontinuation in 5 patients.

  1. Vermersch P, et al. Abstract LBN05, EAN 2020.

 



Posted on